MedTrace Logo

Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy

NCT00205751 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2013-11-25

No results posted yet for this study

Summary

This is an international multi-center prospective, double randomized, open, controlled phase III study with a phase II entrance phase to compare the therapeutic efficacy of thalidomide plus dexamethasone to conventional melphalan plus prednisone in newly diagnosed myeloma patients.

Conditions

Interventions

DRUG

Thalidomide/Dexamethasone vs Melphalan/Prednisone

Sponsors & Collaborators

  • Austrian Forum Against Cancer

    lead OTHER

Principal Investigators

  • Heinz Ludwig, MD,Univ.Prof · Wilhelminenspital 1st medical dep.-center for oncology and hematology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-08-31
Completion
2009-10-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00205751 on ClinicalTrials.gov